News Daily News TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years Michael O'Riordan January 20, 2017
News Daily News Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label? Yael L. Maxwell December 23, 2016
News Daily News After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD Michael O'Riordan December 14, 2016
News Industry News Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan November 29, 2016
News Conference News TCT 2016 Novel SES Fails to Match Xience EES for Chronic Total Occlusions Yael L. Maxwell November 08, 2016
News Conference News TCT 2016 RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent Michael O'Riordan November 08, 2016
News Opinion Editor's Corner TCT 2016 My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway Shelley Wood November 07, 2016
News Industry News Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016 November 03, 2016
News Industry News TCT 2016 Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents November 02, 2016
News Industry News TCT 2016 Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions November 02, 2016
News Conference News TCT 2016 TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES Michael O'Riordan November 02, 2016
News Conference News TCT 2016 New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts Yael L. Maxwell October 31, 2016
Presentation TCT 2016 Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis October 31, 2016
News Industry News Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease October 31, 2016
Presentation TCT 2016 EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone October 31, 2016
Presentation TCT 2016 Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy Presenter: Dean J. Kereiakes, Pieter C. Smits October 30, 2016
Presentation TCT 2016 Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini October 30, 2016
News Conference News TCT 2016 ‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent Michael O'Riordan October 30, 2016
News Conference News TCT 2016 DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term Todd Neale October 30, 2016
News Daily News Now You See It: FDA Approves Absorb Bioresorbable Scaffold Michael O'Riordan July 05, 2016